Mortality rate ratios comparing Europe and North America to South Africa by duration on antiretroviral therapy, adjustment for baseline patient characteristics, and restricted to specific patients and cohorts in sensitivity analyses.

aAdjustments were for baseline gender, CD4 count, clinical stage, viral load, and calendar period and are detailed in Table 3.bMortality rates were predicted from a multivariable model for each region and ART duration for a common group of patients (women aged 30–45 starting ART with a CD4 count 100–199 cells/µl, advanced clinical stage, viral load 4–5 log10 copies/ml, and starting ART in 2004–2007), and then corrected by the inverse of the weighted self-assessed completeness of mortality ascertainment for each region.cBased on cohort-assessed completeness of mortality ascertainment and including seven European and six North American cohorts.dAll North American cohorts reported linking to death registries at least annually, whereas only three European cohorts provided linkage—one annually in patients Mortality rate ratios comparing Europe and North America to South Africa by duration on antiretroviral therapy, adjustment for baseline patient characteristics, and restricted to specific patients and cohorts in sensitivity analyses.